Skip to content

Genetic and Physical Characteristics of Rett Syndrome

Rett Syndrome Natural History: Genetic and Physical Characteristics of Rett Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00299312
Enrollment
10
Registered
2006-03-06
Start date
2006-03-31
Completion date
2015-10-31
Last updated
2017-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MECP2 Duplication Disorder, Rett-related Disorder, Rett Syndrome

Keywords

Loss of Purposeful Hand Use Syndrome, Loss of Communication, Stereotypic Hand Movements, MECP2 mutation, MECP2 duplication, CDKL5 mutation, FOXG1 mutation

Brief summary

Rett Syndrome (RTT) is a genetic brain disorder that occurs almost exclusively in females and is usually caused by a change (mutation) in the gene MECP2. The disorder is characterized by multiple developmental problems, as well as behavioral features, such as repetitive stereotypic hand movements, including hand washing, wringing, and tapping. While there is no cure for RTT, recent advances in the understanding of the disease suggest that the development of new, effective therapies is promising. This study will gather information on the genetic defects that cause RTT, the physical expressions of these defects, and disease progression. In turn, this may direct the development of future treatments. Expanded studies include individuals with MECP2 Duplication disorder, and RTT-related disorders including individuals with MECP2 mutations, but not meeting obligatory criteria for the diagnosis of RTT and individuals with mutations in CDKL5 and FOXG1 some of whom meet criteria for atypical RTT.

Detailed description

RTT is a brain disorder that causes problems with childhood development. It is usually caused by an abnormality (mutation) in the gene MECP2. RTT can cause severe impairments in movement and communication skills, including speech and social interaction. The first signs of RTT include loss of acquired speech and loss of purposeful hand use for activities such as eating or playing. Individuals may also develop abnormal walking, repetitive hand movements, such as clapping or wringing, and abnormal breathing while awake. Effective treatments for RTT are currently lacking. There is also inadequate information about the link between RTT clinical features and its genetic basis. In order to prepare for future clinical trials that may lead to effective therapies, it is important to collect accurate information about the characteristics of RTT and the pattern of disease progression. This study will gather historical and physical examination data to establish phenotype-genotype correlations. Data on survival and quality of life in females with RTT and males with MECP2 gene mutations will also be evaluated. MECP2 Duplication disorder affects principally males who have one and rarely more than one additional copy of MECP2 as well as a variable number of other duplicated genes. These males have absent spoken language, shuffling gait, epilepsy, and, in some, frequent upper respiratory infections or sinusitis. Mother of these males are generally normal due to favorable skewing of X-chromosome inactivation, but in some instances may have neurodevelop-mental delays. Effective treatments are lacking. It is critical to develop phenotype-genotype correlations and longitudinal natural history data to assist the conduct of clinical trials. RTT-related disorders feature a variety of involvements either due to MECP2, CDKL5, and FOXG1 as well as other potential causes of atypical RTT. Phenotype-genotype studies and longitudinal natural history data are essential to the conduct of future clinical trials. Participants in this observational study will be recruited from the four sites at which the study is being conducted, as well as through the Rare Disease Clinical Research Network and the International Rett Syndrome Association (IRSA). Prior to study entry, potential participants are expected to be tested for a mutation in the MECP2 gene. No treatment will be administered at any time during this study. Study visits will occur every 6 months until the child is 6 years old and once a year thereafter. At each study visit, participants will be examined to assess physical characteristics of the disorder, such as motor behavior and disease severity. Additionally, participants will complete questionnaires about medical history, contact information, and quality of life. The first visit will last approximately 1.5 hours, and every subsequent visit will last approximately 1 hour.

Interventions

None listed

Sponsors

Rare Diseases Clinical Research Network
CollaboratorNETWORK
Greenwood Genetic Center
CollaboratorOTHER
Baylor College of Medicine
CollaboratorOTHER
Boston Children's Hospital
CollaboratorOTHER
University of Rochester
CollaboratorOTHER
Children's Hospital of Philadelphia
CollaboratorOTHER
University of Colorado, Denver
CollaboratorOTHER
Rush University Medical Center
CollaboratorOTHER
UCSF Benioff Children's Hospital Oakland
CollaboratorOTHER
University of California, San Diego
CollaboratorOTHER
Vanderbilt University
CollaboratorOTHER
University of South Florida
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Meets clinical criteria for classic or variant RTT or tests positive for an MECP2 gene mutation or a MECP2 duplication or a mutation in CDKL5 or FOXG1.

Exclusion criteria

* Unwilling or unable to travel to study sites for annual or biannual evaluations

Design outcomes

Primary

MeasureTime frameDescription
Genetic and Physical Characteristics of Rett SyndromeJuly 31, 2019The primary endpoint is to determine the variables related to clinical outcome in terms of genotype and phenotype. The variables include growth, head circumference, stereotypic movements, periodic breathing, epilepsy, scoliosis, and longevity. Summative data are provided by the Clinical Severity Scale (CSS) and the Motor Behavioral Assessment (MBA) and specific neurophysiologic and neuroimaging studies in selected participants.

Secondary

MeasureTime frameDescription
Genetic and Physical Characteristics of Rett syndromeThrough July 31, 2019The principal secondary outcome measures include quality of life assessments of the participants (CHQ) and the principal caregiver (SF-36).

Other

MeasureTime frameDescription
Genetic and Physical Characteristics of Rett Syndrome, MECP2 Duplication disorder, and RTT-related conditionsJuly 31, 2019No other pre-specified outcome measures are planned

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026